Furthermore, we provide evidence that pharmacologically targeting DCAF1 and EZH2 in organoid and xenograft models is sufficient to impair their ability to induce oncogenic gene silencing as well as colonic tumor growth. The gene discussed is DCAF1; the disease is colonic neoplasm.